ES2365258T3 - Derivados de tiazol condensados como inhibidores de quinasa. - Google Patents

Derivados de tiazol condensados como inhibidores de quinasa. Download PDF

Info

Publication number
ES2365258T3
ES2365258T3 ES07733382T ES07733382T ES2365258T3 ES 2365258 T3 ES2365258 T3 ES 2365258T3 ES 07733382 T ES07733382 T ES 07733382T ES 07733382 T ES07733382 T ES 07733382T ES 2365258 T3 ES2365258 T3 ES 2365258T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
dialkyl
pyrazolyl
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07733382T
Other languages
English (en)
Spanish (es)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile CRÉPY
Anne Marie Foley
Richard Jeremy Franklin
Alan Findlay Haughan
Helen Tracey Horsley
William Mark Jones
Bénédicte Irma Léonce Frédérique LALLEMAND
Stephen Robert Mack
Trevor Morgan
Patrick Marie Ghislain Pasau
David Jonathan Phillips
Verity Margaret Sabin
George Martin Buckley
Kerry Jenkins
Benjamin Garfield Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2365258T3 publication Critical patent/ES2365258T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES07733382T 2006-06-26 2007-06-26 Derivados de tiazol condensados como inhibidores de quinasa. Active ES2365258T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0612644 2006-06-26
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
GB0620062 2006-10-10

Publications (1)

Publication Number Publication Date
ES2365258T3 true ES2365258T3 (es) 2011-09-27

Family

ID=38671000

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07733382T Active ES2365258T3 (es) 2006-06-26 2007-06-26 Derivados de tiazol condensados como inhibidores de quinasa.
ES08775774T Active ES2416364T3 (es) 2006-06-26 2008-06-24 Derivados de tiazol condensados como inhibidores de cinasas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08775774T Active ES2416364T3 (es) 2006-06-26 2008-06-24 Derivados de tiazol condensados como inhibidores de cinasas

Country Status (20)

Country Link
US (3) US8242116B2 (Direct)
EP (2) EP2035436B1 (Direct)
CN (1) CN101687885B (Direct)
AT (1) ATE510840T1 (Direct)
AU (1) AU2008269577B2 (Direct)
CA (1) CA2692085C (Direct)
CO (1) CO6270229A2 (Direct)
CY (1) CY1114419T1 (Direct)
DK (1) DK2170906T3 (Direct)
EA (1) EA017187B1 (Direct)
ES (2) ES2365258T3 (Direct)
HR (1) HRP20130523T1 (Direct)
IL (1) IL202659A0 (Direct)
ME (1) ME01592B (Direct)
MX (1) MX2009013740A (Direct)
MY (1) MY148852A (Direct)
PL (1) PL2170906T3 (Direct)
PT (1) PT2170906E (Direct)
RS (1) RS52824B (Direct)
WO (1) WO2008001076A1 (Direct)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
AU2009233951B2 (en) 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
WO2010011871A2 (en) * 2008-07-23 2010-01-28 The Regents Of The University Of California Methods and compositions for providing salicylic acid-independent pathogen resistance in plants
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
WO2010096389A1 (en) 2009-02-17 2010-08-26 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
JP2012520887A (ja) * 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2010135504A1 (en) 2009-05-20 2010-11-25 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as pi3 kinase inhibitors
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
BR112012003955A2 (pt) 2009-08-20 2017-09-26 Karus Therapeutics Ltd compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase
SG181716A1 (en) 2009-12-18 2012-07-30 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
NZ600603A (en) * 2009-12-18 2013-07-26 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mglur5 receptors
WO2011157663A1 (de) 2010-06-15 2011-12-22 Bayer Cropscience Ag Neue ortho-substituierte arylamid-derivate
WO2012042006A1 (en) 2010-10-01 2012-04-05 Basf Se Imine compounds
KR20140091462A (ko) * 2010-10-13 2014-07-21 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 그의 용도
US20140018347A1 (en) * 2010-11-24 2014-01-16 Exelixis, Inc. BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
SG11201402237WA (en) 2011-12-22 2014-09-26 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2014144659A1 (en) 2013-03-14 2014-09-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
EP2970137A1 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
JP2016518336A (ja) 2013-03-14 2016-06-23 エピザイム,インコーポレイティド Prmt1阻害剤としてのピラゾール誘導体およびその使用
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153226A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970133B1 (en) 2013-03-14 2018-10-24 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3060548B1 (de) * 2013-10-21 2018-10-10 Umicore AG & Co. KG Monoarylierung aromatischer amine
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
BR112021013105A2 (pt) * 2019-01-08 2021-09-21 Kyorin Pharmaceutical Co., Ltd. Inibidor de 15-pgdh
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents

Also Published As

Publication number Publication date
CY1114419T1 (el) 2016-08-31
DK2170906T3 (da) 2013-06-24
CA2692085C (en) 2015-10-13
EP2170906B1 (en) 2013-04-03
WO2008001076A1 (en) 2008-01-03
AU2008269577B2 (en) 2012-12-20
PT2170906E (pt) 2013-06-25
CN101687885A (zh) 2010-03-31
CA2692085A1 (en) 2008-12-31
US20110003785A1 (en) 2011-01-06
EP2035436B1 (en) 2011-05-25
US8338592B2 (en) 2012-12-25
PL2170906T3 (pl) 2013-08-30
US8710054B2 (en) 2014-04-29
EP2035436A1 (en) 2009-03-18
HRP20130523T1 (en) 2013-07-31
MX2009013740A (es) 2010-02-01
US20130079330A1 (en) 2013-03-28
RS52824B (Direct) 2013-10-31
CO6270229A2 (es) 2011-04-20
ES2416364T3 (es) 2013-07-31
US8242116B2 (en) 2012-08-14
ATE510840T1 (de) 2011-06-15
IL202659A0 (en) 2010-06-30
EA201000038A1 (ru) 2010-06-30
EP2170906A1 (en) 2010-04-07
EA017187B1 (ru) 2012-10-30
AU2008269577A1 (en) 2008-12-31
CN101687885B (zh) 2012-08-22
US20100137302A1 (en) 2010-06-03
MY148852A (en) 2013-06-14
ME01592B (me) 2014-09-20

Similar Documents

Publication Publication Date Title
ES2365258T3 (es) Derivados de tiazol condensados como inhibidores de quinasa.
US8217176B2 (en) Fused heterocyclic derivative and use thereof
ES2505270T3 (es) Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer
AU2017228385B2 (en) Substituted indole Mcl-1 inhibitors
AU2007231577B2 (en) c-MET protein kinase inhibitors for the treatment of proliferative disorders
US9714248B2 (en) Therapeutically active pyrazolo-pyrimidine derivatives
ES2372540T3 (es) Activadores de glucocinasa.
MD3448859T2 (ro) Compoziții de pirolopirol în calitate de activatori ai piruvatkinazei (PKR)
CA2925624A1 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
KR20130049766A (ko) 트리사이클릭 피라졸 아민 유도체
BRPI0709171A2 (pt) ativadores de glicoquinase, composição, usos dos referidos ativadores e métodos para preparação dos mesmos
EP2471791B1 (en) Fused heterocyclic ring derivative and use thereof
WO2013068458A1 (en) Therapeutically active thiazolo-pyrimidine derivatives
WO2009071895A1 (en) Fused thiazole and thiophene derivatives as kinase inhibitors
US8168634B2 (en) Thiazole derivatives as kinase inhibitors
US8093238B2 (en) Fused thiazole derivatives as kinase inhibitors
KR101577314B1 (ko) 키나제 억제제로서의 접합된 티아졸 유도체
USRE48622E1 (en) Therapeutically active pyrazolo-pyrimidine derivatives
WO2010146351A1 (en) Indolylmethyl-morpholine derivatives as kinase inhibitors
ES2822586T3 (es) Inhibidores de btk de tipo nicotinimida sustituida y su preparación y uso en el tratamiento del cáncer, la inflamación y las enfermedades autoinmunitarias